Genome-wide Analyses Reveal a Highly Conserved Dengue Virus Envelope Peptide Which is Critical for Virus Viability and Antigenic in Humans

Overview

Journal Sci Rep

Specialty Science

Date 2016 Nov 3

PMID 27805018

Citations 6

Authors

Renata C Fleith

Francisco P Lobo

Paula F Dos Santos

Mariana M Rocha

Juliano Bordignon

Daisy M Strottmann

Daniel O Patricio

Wander R Pavanelli

Maria Lo Sarzi

Claudia N D Santos

Brian J Ferguson

Daniel S Mansur

Affiliations

Soon will be listed here.

Abstract

Targeting regions of proteins that show a high degree of structural conservation has been proposed as a method of developing immunotherapies and vaccines that may bypass the wide genetic variability of RNA viruses. Despite several attempts, a vaccine that protects evenly against the four circulating Dengue virus (DV) serotypes remains elusive. To find critical conserved amino acids in dengue viruses, 120 complete genomes of each serotype were selected at random and used to calculate conservation scores for nucleotide and amino acid sequences. The identified peptide sequences were analysed for their structural conservation and localisation using crystallographic data. The longest, surface exposed, highly conserved peptide of Envelope protein was found to correspond to amino acid residues 250 to 270. Mutation of this peptide in DV1 was lethal, since no replication of the mutant virus was detected in human cells. Antibodies against this peptide were detected in DV naturally infected patients indicating its potential antigenicity. Hence, this study has identified a highly conserved, critical peptide in DV that is a target of antibodies in infected humans.

Citing Articles

Three highly variable genome regions of the four dengue virus serotypes can accurately recapitulate the CDS phylogeny.

Rodriguez-Aguilar E, Martinez-Barnetche J, Rodriguez M MethodsX. 2022; 9:101859.

PMID: 36187156 PMC: 9516459. DOI: 10.1016/j.mex.2022.101859.

Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.

Qi L, Sun Y, Juraska M, Moodie Z, Magaret C, Heng F Vaccine. 2022; 40(41):5912-5923.

PMID: 36068106 PMC: 9881745. DOI: 10.1016/j.vaccine.2022.08.055.

Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.

Young E, Carnahan R, Andrade D, Kose N, Nargi R, Fritch E Cell Host Microbe. 2020; 27(5):710-724.e7.

PMID: 32407709 PMC: 7309352. DOI: 10.1016/j.chom.2020.04.007.

Identification of highly conserved, serotype-specific dengue virus sequences: implications for vaccine design.

Chong L, Khan A BMC Genomics. 2019; 20(Suppl 9):921.

PMID: 31874646 PMC: 6929274. DOI: 10.1186/s12864-019-6311-z.

Designing antibody against highly conserved region of dengue envelope protein by in silico screening of scFv mutant library.

Rathore A, Sarker A, Gupta R PLoS One. 2019; 14(1):e0209576.

PMID: 30629625 PMC: 6328183. DOI: 10.1371/journal.pone.0209576.

References

Halstead S, ORourke E . Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977; 265(5596):739-41. DOI: 10.1038/265739a0. View

Schwartz L, Halloran M, Durbin A, Longini Jr I . The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine. 2015; 33(29):3293-8. PMC: 4470297. DOI: 10.1016/j.vaccine.2015.05.010. View

Corti D, Voss J, Gamblin S, Codoni G, Macagno A, Jarrossay D . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044):850-6. DOI: 10.1126/science.1205669. View

Cockburn J, Navarro Sanchez M, Fretes N, Urvoas A, Staropoli I, Kikuti C . Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure. 2012; 20(2):303-14. DOI: 10.1016/j.str.2012.01.001. View

Vriend G . WHAT IF: a molecular modeling and drug design program. J Mol Graph. 1990; 8(1):52-6, 29. DOI: 10.1016/0263-7855(90)80070-v. View

Kuno G, Chang G, Tsuchiya K, KARABATSOS N, Cropp C . Phylogeny of the genus Flavivirus. J Virol. 1998; 72(1):73-83. PMC: 109351. DOI: 10.1128/JVI.72.1.73-83.1998. View

Lok S, Kostyuchenko V, Nybakken G, Holdaway H, Battisti A, Sukupolvi-Petty S . Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008; 15(3):312-7. DOI: 10.1038/nsmb.1382. View

Wu X, Yang Z, Li Y, Hogerkorp C, Schief W, Seaman M . Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010; 329(5993):856-61. PMC: 2965066. DOI: 10.1126/science.1187659. View

Walker L, Huber M, Doores K, Falkowska E, Pejchal R, Julien J . Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011; 477(7365):466-70. PMC: 3393110. DOI: 10.1038/nature10373. View

10.

Roehrig J, HUNT A, Johnson A, Hawkes R . Synthetic peptides derived from the deduced amino acid sequence of the E-glycoprotein of Murray Valley encephalitis virus elicit antiviral antibody. Virology. 1989; 171(1):49-60. DOI: 10.1016/0042-6822(89)90509-6. View

11.

Mareze V, Borio C, Bilen M, Fleith R, Mirazo S, Mansur D . Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences. Appl Microbiol Biotechnol. 2015; 100(1):125-33. DOI: 10.1007/s00253-015-6973-7. View

12.

Caskey M, Klein F, Lorenzi J, Seaman M, West Jr A, Buckley N . Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015; 522(7557):487-91. PMC: 4890714. DOI: 10.1038/nature14411. View

13.

Roehrig J, Johnson A, HUNT A, Bolin R, Chu M . Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation. Virology. 1990; 177(2):668-75. DOI: 10.1016/0042-6822(90)90532-v. View

14.

Balazs A, Chen J, Hong C, Rao D, Yang L, Baltimore D . Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011; 481(7379):81-4. PMC: 3253190. DOI: 10.1038/nature10660. View

15.

Modis Y, Ogata S, Clements D, Harrison S . Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004; 427(6972):313-9. DOI: 10.1038/nature02165. View

16.

Holmes E, Twiddy S . The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol. 2003; 3(1):19-28. DOI: 10.1016/s1567-1348(03)00004-2. View

17.

Butrapet S, Childers T, Moss K, Erb S, Luy B, Calvert A . Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion. Virology. 2011; 413(1):118-27. DOI: 10.1016/j.virol.2011.01.030. View

18.

Suzuki R, de Borba L, Dos Santos C, Mason P . Construction of an infectious cDNA clone for a Brazilian prototype strain of dengue virus type 1: characterization of a temperature-sensitive mutation in NS1. Virology. 2007; 362(2):374-83. PMC: 2396755. DOI: 10.1016/j.virol.2006.11.026. View

19.

Christian E, Kahle K, Mattia K, Puffer B, Pfaff J, Miller A . Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci U S A. 2013; 110(46):18662-7. PMC: 3831943. DOI: 10.1073/pnas.1310962110. View

20.

Tharakaraman K, Subramanian V, Cain D, Sasisekharan V, Sasisekharan R . Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell Host Microbe. 2014; 15(5):644-51. PMC: 4258880. DOI: 10.1016/j.chom.2014.04.009. View